Cell-delivered magnetic nanoparticles caused hyperthermia-mediated increased survival in a murine pancreatic cancer model

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 297-306

  Basel, Matthew T ^a   Balivada, Sivasai ^a   Wang, Hongwang ^b   Shrestha, Tej B ^a   Seo, Gwi Moon ^a   Pyle, Marla ^a   Abayaweera, Gayani ^b   Dani, Raj ^b   Koper, Olga B ^b   Tamura, Masaaki ^a   Chikan, Viktor ^b   Bossmann, Stefan H ^b   Troyer, Deryl L ^a  

^a Department of Comparative Medicine   (United States)

^b KANSAS STATE UNIVERSITY   (United States)

Author keywords

Cytotherapy; Disseminated peritoneal carcinomatosis; Nanoparticles; Pancreatic cancer; Targeted magnetic hyperthermia

Indexed keywords

MAGNETIC NANOPARTICLE; PARAMAGNETIC IRON NANOPARTICLE; PARAMAGNETIC IRON OXIDE NANOPARTICLE; UNCLASSIFIED DRUG; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CELL STRAIN RAW264.7; CONTROLLED STUDY; FLOW CYTOMETRY; HYPERTHERMIC THERAPY; IN VIVO STUDY; LIFE EXPECTANCY; MACROPHAGE; MAGNETIC FIELD; MONOCYTE; MOUSE; NONHUMAN; PANCREAS CANCER; SYNTHESIS; TOXICITY; ANIMAL TISSUE; CANCER INFILTRATION; CELL HOMING; DISEASE DURATION; INDUCED HYPOTHERMIA; LIFESPAN; NANOPHARMACEUTICS; ORIENTING RESPONSE; SURVIVAL RATE; SURVIVAL TIME; TEMPERATURE SENSITIVITY;

MURINAE; MUS;

EID: 84863011505     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/ijn.s28344     Document Type: Article

References (61)

1. Philip PA, Mooney M, Jaffe D, et al. Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol. 2009;27(33):5660-5669.
2. Hildebrandt B, Wust P, Ahlers O, et al. The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol. 2002;43(1):33-56.
3. Shecterle LM, St Cyr JA. Whole body hyperthermia as a potential therapeutic option. Cancer Biother. 1995;10(4):253-256.
4. Hildebrandt B, Hegewisch-Becker S, Kerner T, et al; German Interdisciplinary Working Group on Hyperthermia. Current status of radiant whole-body hyperthermia at temperatures.41.5 degrees C and practical guidelines for the treatment of adults. Int J Hyperthermia. 2005;21(2):169-183.
5. Habash RW, Bansal R, Krewski D, Alhafd HT. Thermal therapy, part 2: hyperthermia techniques. Crit Rev Biomed Eng. 2006;34(6):491-542.
6. Sminia P, van der Zee J, Wondergem J, Haveman J. Effect of hyperthermia on the central nervous system: a review. Int J Hyperthermia. 1994;10(1):1-30.
7. Vertree RA, Leeth A, Girouard M, Roach JD, Zwischenberger JB. Whole-body hyperthermia: a review of theory, design and application. Perfusion. 2002;17(4):279-290.
8. Jia D, Liu J. Current devices for high-performance whole-body hyperthermia therapy. Expert Rev Med Devices. 2010;7(3):407-423.
9. Kraybill WG, Olenki T, Evans SS, et al. A phase I study of fever-range whole body hyperthermia (FR-WBH) in patients with advanced solid tumours: correlation with mouse models. Int J Hyperthermia. 2002;18(3):253-266.
10. Jia D, Rao W, Wang C, et al. Inhibition of B16 murine melanoma metastasis and enhancement of immunity by fever-range whole body hyperthermia. Int J Hyperthermia. 2011;27(3):275-285.
11. Ai J, Biazar E, Jafarpour M, et al. Nanotoxicology and nanoparticle safety in biomedical designs. Int J Nanomedicine. 2011;6:1117-1127.
12. Chen B, Wu W, Wang X. Magnetic iron oxide nanoparticles for tumor-targeted therapy. Curr Cancer Drug Targets. 2011;11(2):184-189.
13. Soenen SJ, Himmelreich U, Nuytten N, De Cuyper M. Cytotoxic effects of iron oxide nanoparticles and implications for safety in cell labelling. Biomaterials. 2011;32(1):195-205.
14. Suh JS, Lee JY, Choi YS, et al. Effcient labeling of mesenchymal stem cells using cell permeable magnetic nanoparticles. Biochem Biophys Res Commun. 2009;379(3):669-675.
15. Trahms L, Fannin PC, Kotitz R. Time domain study of Brownian and Neel relaxation in ferrofuids. J Magn Magn Mater. 1995;149(1-2):42-46.
16. Pakhomov AB, Bao Y, Krishnan KM. Effects of surfactant friction on Brownian magnetic relaxation in nanoparticle ferrofuids. J Appl Phys. 2005;97(10):10Q305/301-310Q305/303.
17. Shapiro MG, Atanasijevic T, Faas H, Westmeyer GG, Jasanoff A. Dynamic imaging with MRI contrast agents: quantitative considerations. Magn Reson Imaging. 2006;24(4):449-462.
18. Shinkai M, Yanase M, Suzuki M, et al. Intracellular hyperthermia for cancer using magnetite cationic liposomes. J Magn Magn Mater. 1999;194(1-3):176-184.
19. Le B, Shinkai M, Kitade T, et al. Preparation of tumor-specific magnetoliposomes and their application for hyperthermia. J Chem Eng Jpn. 2001;34(1):66-72.
20. Ito A, Shinkai M, Honda H, et al. Heat shock protein 70 expression induces antitumor immunity during intracellular hyperthermia using magnetite nanoparticles. Cancer Immunol Immunother. 2003;52(2): 80-88.
21. Jordan A, Scholz R, Maier-Hauff K, et al. The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma. J Neurooncol. 2006;78(1):7-14.
22. Jordan A, Scholz R, Wust P, et al. Effects of magnetic fuid hyperthermia (MFH) on C3H mammary carcinoma in vivo. Int J Hyperthermia. 1997;13(6):587-605.
23. Jordan A, Scholz R, Wust P, et al. Endocytosis of dextran and silan-coated magnetite nanoparticles and the effect of intracellular hyperthermia on human mammary carcinoma cells in vitro. J Magn Magn Mater. 1999;194(1-3):185-196.
24. Hilger I, Andra W, Hergt R, Hiergeist R, Schubert H, Kaiser WA. Electromagnetic heating of breast tumors in interventional radiology: in vitro and in vivo studies in human cadavers and mice. Radiology. 2001;218(2):570-575.
25. Johannsen M, Thiesen B, Jordan A, et al. Magnetic fuid hyperthermia (MFH) reduces prostate cancer growth in the orthotopic Dunning R3327 rat model. Prostate. 2005;64(3):283-292.
26. Ohno T, Wakabayashi T, Takemura A, et al. Effective solitary hyper-thermia treatment of malignant glioma using stick type CMC-magnetite. In vivo study. J Neurooncol. 2002;56(3):233-239.
27. Kawai N, Futakuchi M, Yoshida T, et al. Effect of heat therapy using magnetic nanoparticles conjugated with cationic liposomes on prostate tumor in bone. Prostate. 2008;68(7):784-792.
28. Krishnan S, Diagaradjane P, Cho SH. Nanoparticle-mediated thermal therapy: evolving strategies for prostate cancer therapy. Int J Hyperthermia. 2010;26(8):775-789.
29. Aboody KS, Brown A, Rainov NG, et al. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci U S A. 2000;97(23):12846-12851.
30. Arbab AS, Pandit SD, Anderson SA, et al. Magnetic resonance imaging and confocal microscopy studies of magnetically labeled endothelial progenitor cells traffcking to sites of tumor angiogenesis. Stem Cells. 2006;24(3):671-678.
31. De Palma M, Mazzieri R, Politi LS, et al. Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell. 2008;14(4):299-311.
32. Ganta C, Chiyo D, Ayuzawa R, et al. Rat umbilical cord stem cells completely abolish rat mammary carcinomas with no evidence of metastasis or recurrence 100 days post-tumor cell inoculation. Cancer Res. 2009;69(5):1815-1820.
33. Nakamizo A, Marini F, Amano T, et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res. 2005;65(8):3307-3318.
34. Rachakatla RS, Marini F, Weiss ML, Tamura M, Troyer D. Development of human umbilical cord matrix stem cell-based gene therapy for experimental lung tumors. Cancer Gene Ther. 2007;14(10):828-835.
35. Rachakatla RS, Pyle MM, Ayuzawa R, et al. Combination treatment of human umbilical cord matrix stem cell-based interferon-beta gene therapy and 5-fluorouracil significantly reduces growth of metastatic human breast cancer in SCID mouse lungs. Cancer Invest. 2008;26(7):662-670.
36. Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, Andreeff M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res. 2002;62(13): 3603-3608.
37. Studeny M, Marini FC, Dembinski JL, et al. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst. 2004;96(21):1593-1603.
38. Rachakatla R, Balivada S, Seo GM, et al. Attenuation of mouse melanoma by A/C magnetic feld after delivery of bi-magnetic nanoparticles by neural progenitor cells. ACS Nano. 2010;4(12):7093-7104.
39. Solinas G, Germano G, Mantovani A, Allavena P. Tumor- associated macrophages (TAM) as major players of the cancer-related infammation. J Leukoc Biol. 2009;86(5):1065-1073.
40. Strik HM, Hulper P, Erdlenbruch B, et al. Models of monocytic invasion into glioma cell aggregates. Anticancer Res. 2006;26(2A):865-871.
41. Matsui M, Shimizu Y, Kodera Y, Kondo E, Ikehara Y, Nakanishi H. Targeted delivery of oligomannose-coated liposome to the omental micrometastasis by peritoneal macrophages from patients with gastric cancer. Cancer Sci. 2010;101(7):1670-1677.
42. Muthana M, Giannoudis A, Scott SD, et al. Use of macrophages to target therapeutic adenovirus to human prostate tumors. Cancer Res. 2011;71(5):1805-1815.
43. Baek SK, Makkouk AR, Krasieva T, Sun CH, Madsen SJ, Hirschberg H. Photothermal treatment of glioma; an in vitro study of macrophage-mediated delivery of gold nanoshells. J Neurooncol. 2011;104(2): 439-448.
44. Doi C, Maurya DK, Pyle MM, Troyer D, Tamura M. Cytotherapy with naive rat umbilical cord matrix stem cells signifcantly attenuates growth of murine pancreatic cancer cells and increases survival in syngeneic mice. Cytotherapy. 2010;12(3):408-417.
45. Zhang G, Liao Y, Baker I. Surface engineering of core/shell iron/iron oxide nanoparticles from microemulsions for hyperthermia. Mater Sci Eng C Mater Biol Appl. 2010;30(1):92-97.
46. Zeng Q, Baker I, Loudis JA, Liao Y, Hoopes PJ, Weaver JB. Fe/Fe oxide nanocomposite particles with large specifc absorption rate for hyperthermia. Appl Phys Lett. 2007;90(23):233112-233115.
47. Carpenter EE, Sims JA, Wienmann JA, Zhou WL, O'Connor CJ. Magnetic properties of iron and iron platinum alloys synthesized via microemulsion techniques. J Appl Phys. 2000;87(9):5615-5617.
48. Glavee GN, Klabunde KJ, Sorensen CM, Hadjipanayis GC. Chemistry of borohydride reducton of iron(II) and iron(III) ions in aqueous and non-aqueous media. Formation of nanoscale Fe, FeB and Fe2B powders. Inorg Chem. 1995;34(1):28-35.
49. Stuart H, Ridley N. Lattice parameters and Curie-point anomalies of iron-cobalt alloys. J Phys D Appl Phys. 1969;2(4):485-492.
50. Mefford OT, Saville S, Qi B. Controlled surface functionalization of iron-oxide nanoparticles for feld responsive biomedical applications. PMSE Reprints. 2009;101:1569.
51. Hong R, Fischer NO, Emrick T, Rotello VM. Surface PEGylation and ligand exchange chemistry of FePt nanoparticles for biological applications. Chem Mater. 2005;17(18):4617-4621.
52. Jordan A, Wust P, Fahling H, John W, Hinz A, Felix R. Inductive heating of ferrimagnetic particles and magnetic fluids: physical evaluation of their potential for hyperthermia. Int J Hyperthermia. 1993;9(1):51-68.
53. Appenheimer MM, Chen Q, Girard RA, Wang WC, Evans SS. Impact of fever-range thermal stress on lymphocyte-endothelial adhesion and lymphocyte traffcking. Immunol Invest. 2005;34(3):295-323.
54. Calderwood SK, Theriault JR, Gong J. How is the immune response affected by hyperthermia and heat shock proteins? Int J Hyperthermia. 2005;21(8):713-716.
55. Chen T, Guo J, Yang M, Zhu X, Cao X. Chemokine-containing exosomes are released from heat-stressed tumor cells via lipid raft-dependent pathway and act as effcient tumor vaccine. J Immunol. 2011;186(4):2219-2228.
56. Fuggetta MP, Alvino E, Tricarico M, et al. In vitro effect of hyper-thermia on natural cell-mediated cytotoxicity. Anticancer Res. 2000;20(3A):1667-1672.
57. Ito A, Honda H, Kobayashi T. Cancer immunotherapy based on intracellular hyperthermia using magnetite nanoparticles: a novel concept of "heat-controlled necrosis" with heat shock protein expression. Cancer Immunol Immunother. 2006;55(3):320-328.
58. Manjili MH, Wang XY, Park J, et al. Cancer immunotherapy: stress proteins and hyperthermia. Int J Hyperthermia. 2002;18(6):506-520.
59. Milani V, Noessner E. Effects of thermal stress on tumor antigenicity and recognition by immune effector cells. Cancer Immunol Immunother. 2006;55(3):312-319.
60. Segal BH, Wang XY, Dennis CG, et al. Heat shock proteins as vaccine adjuvants in infections and cancer. Drug Discov Today. 2006; 11(11-12):534-540.
61. Muthana M, Multhoff G, Pockley AG. Tumour infltrating host cells and their signifcance for hyperthermia. Int J Hyperthermia. 2010;26(3): 247-255.